Research ExplorerPublicationsRelapse patterns and outcome after relapse in standard risk ...

Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study

Standard

Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. / Sabel, Magnus; Fleischhack, Gudrun; Tippelt, Stephan; Gustafsson, Göran; Doz, François; Kortmann, Rolf; Massimino, Maura; Navajas, Aurora; von Hoff, Katja; Rutkowski, Stefan; Warmuth-Metz, Monika; Clifford, Steven C; Pietsch, Torsten; Pizer, Barry; Lannering, Birgitta; SIOP-E Brain Tumour Group.

In: J NEURO-ONCOL, Vol. 129, No. 3, 09.2016, p. 515-24.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Sabel, M, Fleischhack, G, Tippelt, S, Gustafsson, G, Doz, F, Kortmann, R, Massimino, M, Navajas, A, von Hoff, K, Rutkowski, S, Warmuth-Metz, M, Clifford, SC, Pietsch, T, Pizer, B, Lannering, B & SIOP-E Brain Tumour Group 2016, 'Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study', J NEURO-ONCOL, vol. 129, no. 3, pp. 515-24. https://doi.org/10.1007/s11060-016-2202-1

APA

Sabel, M., Fleischhack, G., Tippelt, S., Gustafsson, G., Doz, F., Kortmann, R., Massimino, M., Navajas, A., von Hoff, K., Rutkowski, S., Warmuth-Metz, M., Clifford, S. C., Pietsch, T., Pizer, B., Lannering, B., & SIOP-E Brain Tumour Group (2016). Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J NEURO-ONCOL, 129(3), 515-24. https://doi.org/10.1007/s11060-016-2202-1

Vancouver

Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J NEURO-ONCOL. 2016 Sep;129(3):515-24. https://doi.org/10.1007/s11060-016-2202-1

Bibtex

@article{8ec5b4571bf24c0dbeb3e3d4737508c0,
title = "Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study",
abstract = "The HIT-SIOP-PNET4 randomised trial for standard risk medulloblastoma (MB) (2001-2006) included 338 patients and compared hyperfractionated and conventional radiotherapy. We here report the long-term outcome after a median follow up of 7.8 years, including detailed information on relapse and the treatment of relapse. Data were extracted from the HIT Group Relapsed MB database and by way of a specific case report form. The event-free and overall (OS) survival at 10 years were 76 ± 2 % and 78 ± 2 % respectively with no significant difference between the treatment arms. Seventy-two relapses and three second malignant neoplasms were reported. Thirteen relapses (18 %) were isolated local relapses in the posterior fossa (PF) and 59 (82 %) were craniospinal, metastatic relapses (isolated or multiple) with or without concurrent PF disease. Isolated PF relapse vs all other relapses occurred at mean/median of 38/35 and 28/26 months respectively (p = 0.24). Late relapse, i.e. >5 years from diagnosis, occurred in six patients (8 %). Relapse treatment consisted of combinations of surgery (25 %), focal radiotherapy (RT 22 %), high dose chemotherapy with stem cell rescue (HDSCR 21 %) and conventional chemotherapy (90 %). OS at 5 years after relapse was 6.0 ± 4 %. In multivariate analysis; isolated relapse in PF, and surgery were significantly associated with prolonged survival whereas RT and HDSCR were not. Survival after relapse was not related to biological factors and was very poor despite several patients receiving intensive treatments. Exploration of new drugs is warranted, preferably based on tumour biology from biopsy of the relapsed tumour.",
keywords = "Journal Article",
author = "Magnus Sabel and Gudrun Fleischhack and Stephan Tippelt and G{\"o}ran Gustafsson and Fran{\c c}ois Doz and Rolf Kortmann and Maura Massimino and Aurora Navajas and {von Hoff}, Katja and Stefan Rutkowski and Monika Warmuth-Metz and Clifford, {Steven C} and Torsten Pietsch and Barry Pizer and Birgitta Lannering and {SIOP-E Brain Tumour Group}",
year = "2016",
month = sep,
doi = "10.1007/s11060-016-2202-1",
language = "English",
volume = "129",
pages = "515--24",
journal = "J NEURO-ONCOL",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

RIS

TY - JOUR

T1 - Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study

AU - Sabel, Magnus

AU - Fleischhack, Gudrun

AU - Tippelt, Stephan

AU - Gustafsson, Göran

AU - Doz, François

AU - Kortmann, Rolf

AU - Massimino, Maura

AU - Navajas, Aurora

AU - von Hoff, Katja

AU - Rutkowski, Stefan

AU - Warmuth-Metz, Monika

AU - Clifford, Steven C

AU - Pietsch, Torsten

AU - Pizer, Barry

AU - Lannering, Birgitta

AU - SIOP-E Brain Tumour Group

PY - 2016/9

Y1 - 2016/9

N2 - The HIT-SIOP-PNET4 randomised trial for standard risk medulloblastoma (MB) (2001-2006) included 338 patients and compared hyperfractionated and conventional radiotherapy. We here report the long-term outcome after a median follow up of 7.8 years, including detailed information on relapse and the treatment of relapse. Data were extracted from the HIT Group Relapsed MB database and by way of a specific case report form. The event-free and overall (OS) survival at 10 years were 76 ± 2 % and 78 ± 2 % respectively with no significant difference between the treatment arms. Seventy-two relapses and three second malignant neoplasms were reported. Thirteen relapses (18 %) were isolated local relapses in the posterior fossa (PF) and 59 (82 %) were craniospinal, metastatic relapses (isolated or multiple) with or without concurrent PF disease. Isolated PF relapse vs all other relapses occurred at mean/median of 38/35 and 28/26 months respectively (p = 0.24). Late relapse, i.e. >5 years from diagnosis, occurred in six patients (8 %). Relapse treatment consisted of combinations of surgery (25 %), focal radiotherapy (RT 22 %), high dose chemotherapy with stem cell rescue (HDSCR 21 %) and conventional chemotherapy (90 %). OS at 5 years after relapse was 6.0 ± 4 %. In multivariate analysis; isolated relapse in PF, and surgery were significantly associated with prolonged survival whereas RT and HDSCR were not. Survival after relapse was not related to biological factors and was very poor despite several patients receiving intensive treatments. Exploration of new drugs is warranted, preferably based on tumour biology from biopsy of the relapsed tumour.

AB - The HIT-SIOP-PNET4 randomised trial for standard risk medulloblastoma (MB) (2001-2006) included 338 patients and compared hyperfractionated and conventional radiotherapy. We here report the long-term outcome after a median follow up of 7.8 years, including detailed information on relapse and the treatment of relapse. Data were extracted from the HIT Group Relapsed MB database and by way of a specific case report form. The event-free and overall (OS) survival at 10 years were 76 ± 2 % and 78 ± 2 % respectively with no significant difference between the treatment arms. Seventy-two relapses and three second malignant neoplasms were reported. Thirteen relapses (18 %) were isolated local relapses in the posterior fossa (PF) and 59 (82 %) were craniospinal, metastatic relapses (isolated or multiple) with or without concurrent PF disease. Isolated PF relapse vs all other relapses occurred at mean/median of 38/35 and 28/26 months respectively (p = 0.24). Late relapse, i.e. >5 years from diagnosis, occurred in six patients (8 %). Relapse treatment consisted of combinations of surgery (25 %), focal radiotherapy (RT 22 %), high dose chemotherapy with stem cell rescue (HDSCR 21 %) and conventional chemotherapy (90 %). OS at 5 years after relapse was 6.0 ± 4 %. In multivariate analysis; isolated relapse in PF, and surgery were significantly associated with prolonged survival whereas RT and HDSCR were not. Survival after relapse was not related to biological factors and was very poor despite several patients receiving intensive treatments. Exploration of new drugs is warranted, preferably based on tumour biology from biopsy of the relapsed tumour.

KW - Journal Article

U2 - 10.1007/s11060-016-2202-1

DO - 10.1007/s11060-016-2202-1

M3 - SCORING: Journal article

C2 - 27423645

VL - 129

SP - 515

EP - 524

JO - J NEURO-ONCOL

JF - J NEURO-ONCOL

SN - 0167-594X

IS - 3

ER -